Role of Interleukin 23 in Gastrointestinal GVHD
白细胞介素 23 在胃肠道 GVHD 中的作用
基本信息
- 批准号:8961634
- 负责人:
- 金额:$ 38.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-01 至 2019-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffectAllogenicBiologyBone Marrow TransplantationCD4 Positive T LymphocytesCellsClinicalColonComplexComplicationDevelopmentDiseaseEquilibriumEventFosteringFunctional disorderGastrointestinal tract structureGoalsHematopoieticHematopoietic Stem Cell TransplantationHematopoietic stem cellsHomingITGAX geneInflammationInflammatoryIntegrinsInterleukin-10InterleukinsIntestinal Graft Versus Host DiseaseLeadLightMediatingMorbidity - disease rateOrganPathogenicityPathway interactionsPhasePlayPopulationPositioning AttributeProcessProductionReagentReceptor SignalingRegulationRegulatory PathwayRegulatory T-LymphocyteRoleStem cell transplantT-Cell ReceptorT-LymphocyteT-Lymphocyte SubsetsTestingTherapeuticTissuesToxic effectTransgenic MiceTransplant Recipientsbaseclinically relevantclinically significantcytokinedesigngastrointestinalgraft vs host diseaseinsightinterleukin-23mortalitymouse modelneovascularizationnovelpreclinical studypublic health relevancereceptorresearch studystem
项目摘要
DESCRIPTION (provided by applicant): Graft versus host disease (GVHD) is the major complication associated with allogeneic hematopoietic stem cell transplantation. Damage to the gastrointestinal (GI) tract from GVHD is a particularly serious event leading to significant morbidity and mortality. Proinflammatory cytokines play a critical role in the pathophysiology of intestinal GVHD, in part, by activating donor T cell populations which subsequently induce direct tissue damage. In preliminary studies, we have identified interleukin 23 (IL-23) as a pivotal cytokine positioned at the apex of this cytokine cascade that secondarily activates a unique CD4+ IL-23 receptor (IL-23R)-positive T cell population that expresses the β2 integrin, CD11c. The overall goal of this proposal is to define the mechanistic pathways by which this CD4+ T cell subset induces pathological damage and determine the regulatory pathways that counter balance IL-23R-mediated inflammation within the GI tract. Our overall hypothesis is that the β2 integrin, CD11c, defines a novel, pathogenic CD4+ IL-23R+ T cell population that induces colonic inflammation during GVHD, and that is regulated by the Stat3-dependent cytokines, interleukin-10 and interleukin-27. Studies in Specific Aim 1 will be conducted to confirm that CD11c co-expression defines a colitogenic CD4+ IL-23R+ T cell population, determine whether Stat3 dependent cytokines produced during GVHD augment coordinate expression of the IL-23R and CD11c, and examine whether the pathogenicity of β2 integrin-expressing CD4+ T cells is attributable to augmented gut-homing molecule expression on this T cell subset. We will also determine whether this β2 integrin-expressing CD4+ T cell population is able to induce endothelial damage and neovascularization in the colon microenvironment. Studies in Specific Aim 2 will define mechanisms by which CD4+ IL-23R+ T cells are regulated during GVHD. We will test the hypotheses that IL-10 and IL- 27, which are also Stat3 dependent cytokines, play critical roles in the regulation of IL-23R-mediated inflammation in the colon. Proposed experiments will identify and characterize the specific IL-10- producing donor T cell populations most critical for regulating CD4+ IL-23R+ T cells. We will also determine how IL-27 modulates IL-23R-mediated inflammation in the GI tract through effects on both conventional and regulatory T cell populations. These studies will take advantage of unique reagents and transgenic mouse models which will allow us to characterize and define the effects of each of these cytokines in the pathophysiology of gastrointestinal GVHD. The overall objective of this proposal is to develop new insights into the pathophysiology and regulation of GVHD within the GI tract that will foster the development of clinically relevant strategies to mitigate this complication in allogeneic hematopoietic stem cell transplant recipients.
描述(申请人提供):移植物抗宿主病(GVHD)是异基因造血干细胞移植的主要并发症。GVHD对胃肠道(GI)的损害是导致显著发病率和死亡率的特别严重的事件。促炎细胞因子在肠道GVHD的病理生理学中起关键作用,部分通过激活供体T细胞群,随后诱导直接组织损伤。在初步研究中,我们已经确定白细胞介素23(IL-23)是位于该细胞因子级联反应顶点的关键细胞因子,其次级激活表达β2整联蛋白(CD 11 c)的独特CD 4 + IL-23受体(IL-23 R)阳性T细胞群。该提案的总体目标是确定该CD 4 + T细胞亚群诱导病理性损伤的机制途径,并确定平衡胃肠道内IL-23 R介导的炎症的调节途径。我们的总体假设是,β2整合素,CD 11 c,定义了一种新的,致病性的CD 4 + IL-23 R + T细胞群体,在GVHD期间诱导结肠炎症,并由Stat 3依赖性细胞因子,白细胞介素-10和白细胞介素-27调节。将进行特定目标1的研究,以确认CD 11 c共表达定义了致大肠杆菌性CD 4 + IL-23 R + T细胞群,确定GVHD期间产生的Stat 3依赖性细胞因子是否增强了IL-23 R和CD 11 c的协调表达,并检查表达β2整联蛋白的CD 4 + T细胞的致病性是否归因于该T细胞亚群上增强的肠道归巢分子表达。我们还将确定表达β2整合素的CD 4 + T细胞群是否能够诱导结肠微环境中的内皮损伤和新血管形成。Specific Aim 2的研究将定义GVHD期间调节CD 4 + IL-23 R + T细胞的机制。我们将测试的假设,IL-10和IL- 27,这也是Stat 3依赖性细胞因子,在调节IL-23 R介导的炎症在结肠中发挥关键作用。提出的实验将鉴定和表征对调节CD 4 + IL-23 R + T细胞最关键的特异性IL-10产生供体T细胞群。我们还将确定IL-27如何通过对常规和调节性T细胞群的影响来调节IL-23 R介导的胃肠道炎症。这些研究将利用独特的试剂和转基因小鼠模型,这将使我们能够表征和定义这些细胞因子中的每一种在胃肠道GVHD的病理生理学中的作用。该提案的总体目标是对胃肠道内GVHD的病理生理学和调节形成新的见解,这将促进临床相关策略的发展,以减轻同种异体造血干细胞移植受者的这种并发症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William R. Drobyski其他文献
Retinoic Acid Regulates Donor Myeloid Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation in Mice
- DOI:
10.1182/blood-2022-162723 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Xinlei Li;Jianwei Zheng;Dian Zhou;Rachel Limpert;Brian Taylor;Linlu Tian;Xue-Zhong Yu;William R. Drobyski;Xiao Chen - 通讯作者:
Xiao Chen
Single-cell immune profiling reveals a developmentally distinct CD4sup+/sup GM-CSFsup+/sup T-cell lineage that induces GI tract GVHD
单细胞免疫分析揭示了一种发育上独特的 CD4+/GM-CSF+T 细胞谱系,其可诱导胃肠道移植物抗宿主病
- DOI:
10.1182/bloodadvances.2021006084 - 发表时间:
2022-05-10 - 期刊:
- 影响因子:7.100
- 作者:
Clint Piper;Emma Hainstock;Cheng Yin-Yuan;Yao Chen;Achia Khatun;Moujtaba Y. Kasmani;John Evans;James A. Miller;Jack Gorski;Weiguo Cui;William R. Drobyski - 通讯作者:
William R. Drobyski
William R. Drobyski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William R. Drobyski', 18)}}的其他基金
Blockade of IL-23 for the Prevention of Graft Versus Host Disease
阻断 IL-23 用于预防移植物抗宿主病
- 批准号:
10391538 - 财政年份:2021
- 资助金额:
$ 38.29万 - 项目类别:
Blockade of IL-23 for the Prevention of Graft Versus Host Disease
阻断 IL-23 用于预防移植物抗宿主病
- 批准号:
10612787 - 财政年份:2021
- 资助金额:
$ 38.29万 - 项目类别:
Blockade of IL-23 for the Prevention of Graft Versus Host Disease
阻断 IL-23 用于预防移植物抗宿主病
- 批准号:
10209084 - 财政年份:2021
- 资助金额:
$ 38.29万 - 项目类别:
Mechanistic Inflammatory Pathways in Graft Versus Host Disease
移植物抗宿主病的机制炎症途径
- 批准号:
10410432 - 财政年份:2020
- 资助金额:
$ 38.29万 - 项目类别:
Mechanistic Inflammatory Pathways in Graft Versus Host Disease
移植物抗宿主病的机制炎症途径
- 批准号:
10214695 - 财政年份:2020
- 资助金额:
$ 38.29万 - 项目类别:
Mechanistic Inflammatory Pathways in Graft Versus Host Disease
移植物抗宿主病的机制炎症途径
- 批准号:
10627875 - 财政年份:2020
- 资助金额:
$ 38.29万 - 项目类别:
Cannabinoid-mediated mitigation of graft versus host disease: Roles of CB2 receptors and adenosine signaling
大麻素介导的移植物抗宿主病缓解:CB2 受体和腺苷信号传导的作用
- 批准号:
9402352 - 财政年份:2017
- 资助金额:
$ 38.29万 - 项目类别:
Inflammatory Cytokine Networks in Gastrointestinal Tract Graft Versus Host Disease
胃肠道移植物抗宿主病中的炎症细胞因子网络
- 批准号:
10159292 - 财政年份:2015
- 资助金额:
$ 38.29万 - 项目类别:
Inflammatory Cytokine Networks in Gastrointestinal Tract Graft Versus Host Disease
胃肠道移植物抗宿主病中的炎症细胞因子网络
- 批准号:
9903428 - 财政年份:2015
- 资助金额:
$ 38.29万 - 项目类别:
Inflammatory Cytokine Networks in Gastrointestinal Tract Graft Versus Host Disease
胃肠道移植物抗宿主病中的炎症细胞因子网络
- 批准号:
10374903 - 财政年份:2015
- 资助金额:
$ 38.29万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 38.29万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 38.29万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 38.29万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 38.29万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 38.29万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 38.29万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 38.29万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 38.29万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 38.29万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 38.29万 - 项目类别:
Research Grant